Aruvant Receives Orphan Drug Designation for ARU-1801 for the Treatment of Sickle Cell Disease

  • ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia
  • ARU-1801 has been designed to deliver a highly potent gene payload with enhanced anti-sickling properties, allowing for a Reduced Intensity Conditioning (RIC) regimen
SourcePR Newswire/ Aruvant Sciences Jan 22, 2020, 08:00 ET
Published On: March 26, 2020 / Categories: news /